On May 17, 2022 Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, reported that Grant Bogle, President and Chief Executive Officer, and Shefali Agarwal, Senior Medical Advisor and Interim Chief Medical and Development Officer, will present at the H.C. Wainwright Global Investment Conference (Press release, Epizyme, MAY 17, 2022, View Source [SID1234614768]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded fireside chat will be available to play on demand stating at 7:00am EST on Tuesday, May 24, 2022. It can be found in the investor section of the Company’s website at www.epizyme.com and will be archived after 60 days following the presentation.